<DOC>
	<DOC>NCT01301248</DOC>
	<brief_summary>To examine the safety and toxicity of concurrent radiotherapy with cisplatin with the further addition of cetuximab experimental treatment</brief_summary>
	<brief_title>Cisplatin Chemoradiation With or Without Cetuximab for Locoregionally Advanced Squamous Cell Carcinomas (SCC) of the Head and Neck</brief_title>
	<detailed_description>Conventional radiotherapy (65-70 Gy, 1.8 Gy per day) concurrently with weekly cisplatin (40mg/m2) (group A, n=25) or with weekly cisplatin (40mg/m2) and weekly cetuximab 250mg/m2, after initial dose of 400mg/m2) (group B, n=25) is applied (in a 1:1 randomization ratio). Groups will be matched age, sex, PS, and disease site.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>histologically confirmed HNSCC of oral cavity, larynx, oropharynx or hypopharynx; age of 18 years or more adequate liver (SGOT, SGPT, ALP ≤ 3x normal) kidneys (creatinine clearance ≥ 60ml/min heart (no arrythmias, no heart failure) and bone marrow (WBC ≥ 4,000/μL, granulocytes ≥ 1,500/μL, Hb ≥ 10g/dL, platelets ≥ 100,000/μL) function ECOG performance status 0 or 1 and stage III or IVa to b with measurable lesions written informed consent prior radiotherapy chemotherapy concurrent active malignancies pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>locally advanced,</keyword>
	<keyword>unresectable,</keyword>
	<keyword>head and neck squamous cell carcinoma,</keyword>
	<keyword>stage III/IV</keyword>
</DOC>